Pharmosa Biopharm Inc.
TTPEX:687526.65
TWD
-0.40
(-1.48%)
ISIN
TW0006875008
Return %
Stock
S&P 500
1Y
-54.68
14.20
3Y
-67.74
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Pei Kan
- Full Time Employees
- 15
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- No. 66, Sanchong Road Taipei TP Taiwan 11502
- IPO Date
- Mar 25, 2024
- Website
- pharmosa.com.tw
- Similar Companies
- Business
- Pharmosa Biopharm Inc. is a Taiwan-based biotechnology company primarily engaged in the research, development, and commercialization of innovative pharmaceuticals for pulmonary vascular diseases. Founded in 2000 and headquartered in Taiwan, the company specializes in proprietary liposomal drug formulations and inhalation/device combination therapies. Its main products include L606, a sustained-release inhaled liposomal formulation of treprostinil for treating pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), and chronic thromboembolic pulmonary hypertension (CTEPH); and L608, another inhalation/device combination targeting PAH. These products leverage Pharmosa’s proprietary liposomal technology designed to enhance drug delivery, improve patient compliance, and reduce systemic side effects. Pharmosa operates in the biotechnology and pharmaceutical sectors, focusing on chronic and rare pulmonary diseases with a commercial ambition spanning North America, Europe, the Asia-Pacific region, and the MENAT region through strategic partnerships. Notably, in 2023 and 2024, Pharmosa expanded its collaboration with Liquidia Technologies, Inc. to develop and commercialize L606 in North America, supporting late-stage clinical trials and regulatory submissions. In addition, the company entered an in-licensing collaboration with Menagen to distribute L606 within the MENAT region. Pharmosa’s recent clinical progress includes the presentation of Phase I trial results for inhaled liposomal iloprost at the 2025 European Congress of Rheumatology (EULAR), reflecting ongoing innovation in pulmonary hypertension treatments. Recent strategic developments involve advancing L606 through pivotal Phase III clinical trials in the US and preparing for commercial expansion by seeking additional partners and licensing opportunities globally. Pharmosa continues to focus on long-term growth through licensing arrangements that generate royalty revenues and by establishing cost-efficient drug supply production lines. Its business model emphasizes sustainable income from royalties alongside operational efficiencies. The company changed its name to Pharmosa Biopharm Inc. in 2016 and continues to emphasize research-driven development combined with strategic partnerships to maximize global patient access to its novel therapies. Pharmosa Biopharm's key focus areas include sustained-release liposomal drug formulations, inhalation therapies for pulmonary vascular diseases, and medical device combination products, targeting both clinical efficacy and patient convenience in treatment regimens. These products address unmet needs in rare and chronic pulmonary conditions, with a pipeline that includes inhaled therapies designed to improve pharmacokinetics and therapeutic outcomes through advanced drug delivery systems. The company reported a strong gross margin and ongoing investments in clinical development and talent retention to support its technology-driven growth path. In summary, Pharmosa Biopharm Inc. is a research-centric biopharmaceutical company specializing in innovative inhalation therapies for pulmonary hypertension and related diseases, currently advancing late-stage clinical programs and expanding global commercial partnerships to enhance patient access and optimize treatment delivery worldwide.